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ABSTRACT 
Design, Synthesis and Characterization of Peptide-Guided Nanomaterial for Cancer Targeting 
 
 
 
Megan Metcalf 
Department of Chemistry 
Texas A&M University 
 
 
Research Advisor: Dr. Hong-Cai Zhou 
Department of Chemistry 
Texas A&M University 
 
 
 Specifically targeting cancer cells is much more efficient than non-targeted treatment 
because it decreases side effects and permits stronger treatment without as a risk of harming 
normal cells. Smart molecular probes and materials capable of passively or actively targeting 
cancerous cells show potential in cancer treatment for this reason. The combination of Metal-
Organic Frameworks (MOFs) with actively targeting molecules provides an attractive way for 
targeted cancer theranostic methods. In this work, peptide sequences were synthesized that have 
high affinity and specificity towards proteins expressed on the surface of cancer cells. To 
introduce enough flexibility for targeted binding and provide extra functionality, the targeting 
peptide AP2H was further modified with polyethylene glycol (PEG) as a spacer molecule, and 
the peptide RGDG was used in place of RGD in order to use the additional glycine residue as a 
spacer molecule. After solid phase synthesis and cleavage, the resultant peptides were 
characterized with high-performance liquid chromatography (HPLC) and mass spectrometry 
(MS). Biocompatible metal-organic frameworks ZIF-8, UiO-66, and UiO-66-NH2 were 
synthesized. UiO-66-NH2 was functionalized with the peptide sequences to build a targetable 
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delivery system using the MOF to carry molecules, such as fluorescent probes or anticancer 
drugs, directly to tumor cells by using the targeting peptides RGD and AP2H. 
 Doxorubicin (DOX), a typical anticancer drug, was used as a model to determine whether 
the peptide-guided delivery system has the potential for carrying molecular cargos. UV-Vis 
spectrophotometry was used to quantitatively measure the uptake and subsequent release of 
DOX. The DOX-encapsulated MOF paired with a targeting peptide can be promising as a 
targetable delivery system for cancer treatment. 
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ABBREVIATIONS 
 
MOF  Metal-Organic Framework 
RGDG  RGDG amino acid sequence 
AP2H  IHGHHIISVG amino acid sequence 
PEG  polyethylene glycol 
LAPTM4B lysosomal protein transmembrane 4 beta 
DOX  doxorubicin 
HPLC  High Performance Liquid Chromatography 
SEM  Scanning Electron Microscopy 
MS  Mass Spectrometry 
TFA  trifluoroacetic acid 
TIS  triisopropylsilane 
SA  succinate anhydride 
PBS  phosphate buffered saline 
CDI  1,1’- carbonyldiimidazole 
HBTU  (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
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CHAPTER I 
INTRODUCTION 
 
Cancer, as a global threat to public health, has warranted extensive attention from 
researchers in a variety of fields. Chemotherapy is one of the most important treatments for 
cancer but is still challenged by its severe side effects to healthy cells due to the lack of 
selectivity. To address this, targetable chemical probes and materials for precise cancer diagnosis 
and treatment are critically needed. 
Proteins specifically overexpressed on cancer cells are excellent targets for cancer 
treatment and have been explored as targets for the development of cancer-detecting bioprobes. 
These probes are required to exhibit high affinity, selectivity, and sensitivity for their target 
proteins.1 Nowadays, increasingly more peptides are discovered that recognize cancer-related 
molecular events. For example, RGD is a well-known tripeptide sequence which can specifically 
bind integrin αvβ3, a transmembrane protein commonly overexpressed in cancer cells. Due to the 
critical role of integrin αvβ3 in regulating tumor growth and metastasis, various RGD-based 
probes have been developed for cancer analysis.2,3 Recently, the decapeptide AP2H has been 
reported to recognize a tumor-related protein, lysosomal protein transmembrane 4 beta 
(LAPTM4B), and has increased affinity for LAPTM4B in the characteristic low-pH environment 
of tumor cells.1,4  
Metal-Organic Frameworks (MOFs) are a class of porous coordination polymers 
composed of inorganic building blocks with organic linkers. The tunability of MOFs in 
morphology, size, and porosity allows flexibility in synthesizing nanomaterials with a desired 
function. The highly porous structure of MOFs makes them attractive carriers for different 
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molecules, such as imaging agents and chemotherapeutics.5-8 For biomedical and analytical 
applications of MOFs, there are challenges including controlling size in nanoscale, 
biocompatibility, and stability in an aqueous environment. In addition, cell penetrability and non-
specificity are also major concerns. 
Herein, aimed at developing a targeted delivery nano-system for cancer treatment, cancer 
cell-targeting peptides were synthesized for the functionalization of MOFs. Two peptide 
sequences, RGD and AP2H, were chosen as the targeting vehicles. To introduce enough 
flexibility for cell binding and extra functionality, the AP2H peptide was further modified with a 
spacer, and the RGD peptide was lengthened to RGDG. The peptides were characterized via 
HPLC and MS. As the transporters, MOFs built from different metal ions and ligands were 
prepared. MOFs like ZIF-8 and UiO-66, which contain metal ions Zn(II) and Zr(IV) 
respectively, were chosen due to stability in water and safety of their metal ions in biological 
systems.6-8 The size and morphology of the MOFs were observed with scanning electronic 
microscopy (SEM). The MOF UiO-66-NH2 was synthesized for functionalization of the MOF 
with a targeting peptide sequence by making use of NH2 groups on the ligands of the MOF. The 
coupled MOF and targeting peptide are designed to function as the aforementioned nanoscale 
delivery system, with the targeting peptide guiding the MOF and its cargo directly to tumor cells. 
Doxorubicin is an anticancer drug on the World Health Organization’s list of essential 
medicines.9 A potential cargo for the delivery system, doxorubicin (DOX), was chosen to test the 
system due to its fluorescent properties and well-known systemic toxicity. UV-Vis 
spectrophotometry was used to quantitatively determine the uptake and subsequent release of 
DOX from UiO-66 and UiO-66-NH2.  
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CHAPTER II 
METHODS 
Synthesis. 
Peptide synthesis. 
Peptides were synthesized manually by the solid-phase FMOC synthesis approach, as 
shown in Scheme 1. An FMOC-Gly-Wang resin was used as the starting material in both 
peptides. The spacer molecule with AP2H, PEG, was also coupled while the peptide sequence 
remained on the resin. After cleavage, the products were obtained as solid powders. 
 
Scheme 1. FMOC solid phase synthesis procedure. 
 
HBTU was used as the activating reagent. A 20% piperidine in DMF solution was used 
for removal of the FMOC temporary protecting groups. After the peptide sequence was 
assembled, cleavage of peptides from the resin and global side-chain deprotection were carried 
out with a freshly prepared TFA cocktail (95% TFA, 2.5% H2O, and 2.5% TIS). The product 
was analyzed on a SHIMADZU HPLC system (Kyoto, Japan). 
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Modification of peptide AP2H. 
The modification of the peptide sequence was carried out via on-resin synthesis. After the 
amino acids of AP2H were assembled, the FMOC group was removed and a 2-fold excess of 
PEG5 was added. After coupling and washing, a 3-fold excess of succinate anhydride (SA) was 
introduced. The resultant product was then cleaved from the resin with a freshly prepared TFA 
cocktail (95% TFA, 2.5% H2O and 2.5% TIS). 
Synthesis of ZIF-8. 
ZIF-8 was synthesized according to reported procedures.10 Briefly, methanolic stock 
solutions of Zn(NO3)2•6H2O (25 mM) and of 2-methylimidazole (mIm) (50 mM) were prepared. 
ZIF-8 was obtained by mixing 10 ml Zn(NO3)2 stock solution and 10 ml mIm stock solution for 
30 minutes at room temperature. 
Synthesis of UiO-66. 
UiO-66 was synthesized using two different methods, according to reported procedures.11 
In the first method, zirconyl chloride octahydrate was used. Terephthalic acid (50 mg, 0.24 
mmol) was dissolved in 1 ml of DMF. In a separate vial, zirconyl chloride octahydrate (21 mg, 
0.066 mmol) was dissolved in 3 ml of DMF. The two solutions were mixed together in a 
scintillation vial, and acetic acid (300 µl) was added to the reaction mixture. The solution was 
heated at 85˚C for 18 h. This MOF was used for SEM. 
In the second method, zirconium(IV) chloride was used. In a vial, 77 mg of ZrCl4, 52 mg 
of terephthalic acid, 620 mg of benzoic acid, 6 mL of DMF, and 75 µL of concentrated HCl were 
combined. The solution was heated at 120˚C for 48 h. 
Synthesis of UiO-66-NH2. 
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UiO-66-NH2 was synthesized by the same procedure as the second synthesis method for 
UiO-66 but using 2-aminoterephthalic acid in place of terephthalic acid.11 
Coupling. 
Coupling of UiO-66-NH2 to RGDG. 
The coupling of RGDG to the MOF was done by a three-step approach, outlined in 
Scheme 2. This approach attaches a carboxylic acid to the amine groups of the MOF, then 
attaches the N-terminal of the peptide to the carboxylic acid on the MOF in order to avoid 
possible side reactions involving the carboxylic acid group in the aspartic acid side chain of 
RGDG. First, 2.9 mg of SA, 5 µL of DIEA, and 0.1 mL of DMF were combined, then 5 mg of 
UiO-66-NH2 and 0.4 mL of DMF was added and the solution was stirred overnight. In the 
second step, 1.2 mg of CDI and 3 µL of DIEA were added to the solution, which was then stirred 
2 h. In the third step, 5 mg HBTU, 3 µL of DIEA, and 0.6 mL of a solution of RGDG in 
methanol were added along with 0.3 mL of DMF and the solution was stirred overnight. HPLC 
was used to compare relative concentrations of RGDG in the reaction solution before and after 
the coupling reaction. 
Coupling of UiO-66-NH2 to AP2H. 
 The coupling of AP2H to the MOF was done by a single step reaction, outlined in 
Scheme 2, which links the C-terminal of the amino acid chain to the amine groups on the MOF. 
To a vial, 9.8 mg of HBTU, 0.5 mL of AP2H in H2O, and 0.4 mL of DMF were added, then 80 
µL and 8 mg of UiO-66-NH2 were added and the solution was stirred overnight. HPLC was used 
to compare relative concentrations of AP2H in the reaction solution before and after the coupling 
reaction. 
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Scheme 2. Two approaches to coupling peptide to UiO-66-NH2. 
 
Doxorubicin Uptake. 
 A solution was prepared of 0.5 mg/mL of DOX in 10% DMF in PBS. In a vial, 1.5 mL of 
the DOX solution was added to 4.4 mg of UiO-66-NH2. The solution was stirred for 2-3 days. 
The solution was then centrifuged, and supernatant removed to compare to the initial DOX 
solution. The MOF was washed with a 10% DMF in PBS solution for comparison with the initial 
DOX solution to determine DOX release from the MOF. The MOF was also washed with DMF 
after the PBS washes. The DOX uptake procedure and washes were repeated with UiO-66 
instead of UiO-66-NH2.  
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CHAPTER III 
RESULTS 
 
Synthesis. 
Two peptides, RGD and AP2H with high affinity binding to cancer-related proteins were 
chosen as the targeting sequences. Their targets, integrin αvβ3 and LAPTM4B, are membrane 
anchored proteins, which are feasible targets for the recognition of cancer cells.3,4 To avoid 
possible steric hindrance during the binding of peptides towards proteins, spacers were 
introduced to both peptide sequences. For RGD, an additional glycine was added in the 
carboxylic terminal to make RGDG. For AP2H, polyethylene glycol (PEG5) was incorporated. 
The synthesized peptides RGDG, and AP2H-PEG5 were analyzed with HPLC and mass 
spectrometry. Given that AP2H has a longer sequence, it was also cleaved and characterized 
before the conjugation of PEG5 to ensure correct synthesis. The HPLC chromatograms and MS 
spectra are shown in Figure 1. By integrating the peak areas in the chromatograms, the purities of 
the peptides were calculated. The purity for RGDG is above 90%. AP2H and AP2H-PEG5 were 
both obtained with purities of around 80%. The appearance of m/z signals corresponding to the 
peptides in MS spectra demonstrates the success of the syntheses. 
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Figure 1. HPLC and MS analyses of peptides. (a, c, e) HPLC chromatograms of RGDG, AP2H 
and AP2H-PEG. (b, d, f) MS spectra of RGDG, AP2H and AP2H-PEG. 
 
As the carrier of cargos into cancer cells, the MOFs should be stable and nontoxic in a 
physiological environment. Metal ions such as Zn(II) and Zr(IV) with high biocompatibility 
were chosen for the synthesis of ZIF-8 and UiO-66. As characterized with scanning electronic 
microscopy (SEM), the sizes of the MOFs are around 100 nm (Figure 2). The structure of UiO-
66 is shown in Figure 3. 
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Figure 2. SEM images of ZIF-8 (a) and UiO-66 (b). 
 
 
 
Figure 3. Shown in a is a fundamental building unit of UiO-66, a 6-center metal cluster with 
metal atoms in dark blue, oxygen in light blue, and carbon atoms in magenta. These clusters are 
connected by terephthalate linkers, shown on the right side of a. Demonstrated by b, UiO-66 
takes on a face-centered cubic arrangement. A simplified version of the UiO-66 structure is 
shown in c.12  
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Coupling. 
The nanoscale size of the MOFs can take advantage of the enhanced permeability and 
retention (EPR) effect in tumor vasculature, causing the MOF and its cargo to accumulate within 
tumor cells, which is appealing for passive targeting.13 In preparation for functionalization with 
peptides, UiO-66-NH2 was prepared with the same procedure as that of UiO-66, except 2-
aminoterephthalic acid was used in place of terephthalic acid. The free amino groups on UiO-66-
NH2, from 2-aminoterephthalic acid molecules, can be accessed for modification with peptides. 
The targeting peptide AP2H was combined with UiO-66-NH2 in a single-step procedure. 
As shown in Figures 1 and 4, the peak representing AP2H in the HPLC chromatogram occurs at 
12.5 minutes. This peak on the chromatogram of the solution obtained before coupling is smaller 
than that of the solution obtained after coupling with the MOF. The change in concentration of 
AP2H before and after the reaction could not be determined. 
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Figure 4. HPLC chromatograms of AP2H (a) before and (b) after the coupling reaction with 
reference lines at 12.5 minutes. 
 
The targeting peptide RGDG was conjugated with UiO-66-NH2 in a 3-step reaction. 
Firstly, UiO-66-NH2 was modified with succinic anhydride to introduce carboxylic acid to the 
surface of the MOF, and then the N-terminal of the peptide was attached via peptide bond. 
RGDG was attached to the MOF via the amino group of arginine residue rather than the terminal 
glycine. This method can prevent the MOF from attaching to the carboxylic acid on the aspartic 
acid side chain and is controllable. 
HPLC chromatograms of the RGDG solutions before and after the reaction were 
compared to determine the amount of RGDG that coupled to the MOF. The solutions collected 
a) 
 
 
 
 
 
b) 
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after washing the MOF were also analyzed with HPLC. The retention time of RGDG peptide in 
the HPLC chromatograms is 5 minutes, as shown in Figure 1. However, shown in Figure 5, there 
is no clear peak at 5 minutes for RGDG. Due to the presence of another component of the 
solution, it could not be determined whether there was a change in concentration of RGDG in 
solution. 
 
 
Figure 5. The HPLC chromatograms of RGDG (a) before and (b) after the coupling reaction 
with reference lines at 5 minutes. 
 
Both the RGDG and AP2H coupling reactions had inconclusive results based on the 
HPLC chromatograms. This phenomenon may be due to some ligands or leftover reactants from 
a) 
 
 
 
 
 
b) 
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the MOF that washed out in the solution and overlapped with the peptide peaks in the 
chromatograms. 
Doxorubicin Uptake. 
The ability of UiO-66 and UiO-66-NH2 to encapsulate and transport the anticancer drug 
DOX (Figure 6) was tested. DOX was chosen for its absorbance and fluorescent properties. And 
UV-Vis spectrophotometry was used to quantitatively determine doxorubicin uptake by the 
MOFs. 
 
 
Figure 6. Doxorubicin (DOX) structure. 
 
 Stock solutions of varying concentrations of DOX (10% DMF in PBS) were prepared. 
UV-Vis spectra were obtained for each at 496 nm, which is the peak absorbance for DOX. As 
shown in Figure 7, the calibration curve has a trendline with the following equation, where A 
represents absorbance and c represents concentration: 
 
𝐴 = 2.29 ∗ 𝑐 − 0.0138          (Eq. 1) 
 
The calibration curve is linear and consistent with Beer’s law, as shown below, where L 
is path length and ε is the molar absorptivity constant. 
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𝐴 = 𝜀 ∗ 𝐿 ∗ 𝑐           (Eq. 2) 
 
 
Figure 7. Calibration curve for DOX in PBS added with 10% DMF. 
 
After mixing UiO-66 and UiO-66-NH2 in 5 mg/mL DOX stock solution for varied 
periods (1.5 hours, 2 days and 3 days), the concentration of DOX remaining in each solution was 
measured and compared with the stock solution in order to determine encapsulation efficiency of 
each MOF, as shown in Table 1. 
 
Table 1. DOX uptake by UiO-66-NH2 and UiO-66. 
MOF Mixing 
time 
Absorbance 
at 496 nm 
Concentration 
(mg/mL) 
Mass 
remaining 
(mg) 
Encapsulation 
efficiency 
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UiO-66 2 days 0.503 0.23 0.34 95.5% 
UiO-66-NH2 2 days 0.432 0.19 0.29 96.1% 
UiO-66-NH2 3 days 0.121 0.06 0.09 98.8% 
UiO-66-NH2 1.5 hours 0.465 0.21 0.31 95.8% 
 
 Based on the encapsulation efficiencies of UiO-66-NH2 after varying encapsulation 
times, shown in Table 1, it appears most of the DOX was encapsulated within the first hour and a 
half, while increasing encapsulation times increase encapsulation efficiency by only a small 
amount. This indicates that, despite the relatively large size of the DOX molecule compared to 
the ligand used to form the MOF, 2-aminoterephthalic acid, the uptake is very favorable and 
rapid. 
 Multiple washes were performed to examine the retention strength of the MOFs towards 
DOX. Eluted and released DOX from 6 successive washes with PBS (10% DMF), followed by 3 
washes with DMF was determined with UV-Vis spectroscopy. The mass of DOX removed from 
the MOFs with each wash is listed in Figure 8. 
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Figure 8. DOX removed from MOFs with PBS and DMF washes. 
 
During the PBS washes, continuous release of DOX was detected, suggesting the weak 
adsorption of these DOX molecules on the MOFs. When the solvent was changed to DMF, a 
significant increase in DOX release was detected, especially for UiO-66. After the first DMF 
wash, almost none of the DOX was removed with subsequent washes. Most of the DOX that 
would come off with washes came off with the first DMF wash. As shown in Table 2, the washes 
removed only 12.8% of the DOX in UiO-66-NH2, and 23.5% of the DOX in UiO-66. The total 
released amount of DOX is higher from UiO-66 than that from UiO-66-NH2. This may be 
attributed to non-covalent interaction between DOX and amino groups on UiO-66-NH2. 
 
Table 2. DOX removal from MOFs after PBS and DMF washes. 
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MOF DOX 
encapsulated 
(mg) 
DOX 
removed 
(mg) 
Percent 
removed 
DOX 
removed 
with PBS 
washes 
(mg) 
DOX 
removed 
with DMF 
washes 
(mg) 
DOX 
remaining 
(mg) 
UiO-66 6.992 1.427 23.5% 0.827 0.600 6.073 
UiO-66-NH2 7.368 0.848 12.8% 0.609 0.239 6.652 
 
 After DOX uptake by the MOFs, both UiO-66 and UiO-66-NH2 changed color from 
white and pale yellow, respectively, to red as shown in Figure 9. DOX is a slightly darker color 
of red compared to the color of the MOF with DOX. After the washes, both MOFs retained the 
red color, as well as most of the DOX that had been encapsulated. 
 The MOFs retain much of the DOX encapsulated and encapsulate the DOX relatively 
quickly despite the size of the molecules. It is likely that the DOX interacted with UiO-66 and 
UiO-66-NH2 quite strongly to form a different product. The UiO-66 and UiO-66-NH2 both 
encapsulate DOX to a similar degree, indicating that the results are not exclusively due to the 
amino groups on UiO-66-NH2. Instead, the DOX either reacted with a component of the MOFs 
unrelated to the ligand, or it was successfully taken into the pores of the MOF but could not 
easily be removed once there. 
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Figure 9. UiO-66-NH2 after DOX uptake. 
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CHAPTER IV 
CONCLUSION 
 
Cancer cell-targeting peptides RGDG and AP2H were successfully synthesized and 
characterized. Biocompatible MOFs ZIF-8 and UiO-66 were also prepared with a size of around 
100 nm, which is appealing for biomedical applications. 
UiO-66-NH2 with free amino groups was prepared for coupling to targeting peptide 
sequences. The NH2 groups on the MOF are available for covalent functionalization with 
targeting peptides. HPLC chromatograms obtained of the reaction solution before and after 
peptide coupling were inconclusive due to compounds in solution overlapping with the peptide 
peak. Doxorubicin, a fluorescent anticancer drug, was used to test the uptake of UiO-66-NH2, 
and therefore test a potential cargo for the peptide-guided delivery system. DOX was 
successfully absorbed by the porous MOFs with an encapsulation efficiency of 96.1%. The DOX 
was removed by washing the MOF, but only 12.8% of the DOX taken up by UiO-66-NH2 could 
be removed. 
With the guidance of cancer-cell targeting peptides, cargos encapsulated in MOFs can be 
delivered specifically to cancer cells. The selective targeting of cancer cells is beneficial to 
sensitive detection or specific ablation of cancer, while circumventing serious side effects to 
normal cells. 
Future directions may include investigation of the concept with a variety of other cancer-
targeting peptides and other bio-compatible MOFs. In addition, using cancer-targeting peptides 
may open up other options for cancer probes or anticancer drugs that would not be viable for less 
precise delivery methods.  
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APPENDIX 
 
 
 
Figure 10. UV-Vis spectra of DOX stock solutions of varying concentrations used to calculate a 
calibration curve for DOX concentration. 
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Figure 11. UV-Vis spectra of washes from UiO-66 two-day uptake of DOX. 
 
Figure 12. UV-Vis spectra of solutions from UiO-66 and UiO-66-NH2 two-day uptakes of DOX. 
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Figure 13. UV-Vis spectra of washes from UiO-66-NH2 three-day uptake of DOX. 
 
Figure 14. UV-Vis spectra of washes from UiO-66-NH2 two-day uptake of DOX. 
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Figure 15. UV-Vis spectra of washes from UiO-66-NH2 1.5 h uptake of DOX. 
 
Figure 16. UV-Vis spectra of multiple days of washes from UiO-66-NH2 three-day uptake of 
DOX. 
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Figure 17. UV-Vis spectra of multiple days of washes from UiO-66 two-day uptake of DOX. 
